ponesimod   Click here for help

GtoPdb Ligand ID: 9320

Synonyms: ACT-128800 | ACT128800 | Compound 8bo [PMID:20446681] | Ponvory®
Approved drug Immunopharmacology Ligand
ponesimod is an approved drug (EMA & FDA (2021))
Compound class: Synthetic organic
Comment: Ponesimod (ACT-128800) is an orally active sphingosine-1-phosphate (S1P) receptor modulator [1] that was developed as a disease-modifying therapy (DMT) for multiple sclerosis (MS). The compound is reported as a partial S1P4 and S1P5 receptor agonist, with maximum activity 18% and 42% of that induced by the endogenous ligand S1P (at 10μM ACT-128800) [1].
The INN record for ponesimod stipulates the (2R) stereoisomer ((2Z,5Z)-5-{3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenylmethylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one).
Selective SIP1 receptor agonists are being developed and investigated for immunomodulatory/immunosuppressant potential in autoimmune diseases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 107.66
Molecular weight 460.12
XLogP 3.55
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCCN=C1SC(=Cc2ccc(c(c2)Cl)OCC(CO)O)C(=O)N1c1ccccc1C
Isomeric SMILES CCCN=C1S/C(=C\c2ccc(c(c2)Cl)OC[C@@H](CO)O)/C(=O)N1c1ccccc1C
InChI InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Ponesimod (ACT-128800) progressed through to late stage development for relapsing multiple sclerosis (MS). Clinical trial NCT02425644 evaluated ponesimod against the dihydroorotate dehydrogenase inhibitor MS drug teriflunomide. In a press release (July 2019) Janssen Pharmaceutical reported positive top-line results from NCT02425644 in patients with relapsing MS. The FDA granted approval in March 2021, as a once-daily oral therapy for relapsing forms of MS. EMA approval followed in May of the same year.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Selective S1P1 receptor agonists appear to act as functional antagonists of lymphocyte movement from the lymph nodes to the circulation. Ponesimod causes the retention of lymphocytes in lymph tissues and thereby decreases circulating lymphocyte numbers, and the number of inflammatory cells available to cross into the central nervous system, where they can cause the myelin damage characteristic of MS. In effect S1P1 receptor agonists act as disease-modifying therapeutics (DMTs). Much drug development effort has focussed on DMTs for MS, and this is reviewed in [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02425644 Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis Phase 3 Interventional Actelion